April 6, 2022
SINGAPORE, 6 APRIL 2022 – Over the past decades, Singapore has developed a world-class healthcare system, with leading clinicians and advanced infrastructure, to deliver quality healthcare that is affordable and sustainable.
In 2000, the Government launched the biomedical sciences initiative to build the biomedical industry as the fourth pillar of the economy. This has led to peaks of scientific excellence, robust infrastructure, a pipeline for talent for biomedical research, and translation of discoveries into tangible capabilities and commercial enterprises.
Leveraging these developments to advance healthcare capabilities and create economic value for Singapore, the Consortium for Clinical Research and Innovation, Singapore (CRIS) has been established to bring together five key national R&D, clinical translation and service initiatives that are under the stewardship of the Ministry of Health.
Refer to Annex 1 for more information about each initiative.
“As Singapore’s basic science capabilities and talent base have begun to mature, and as our research initiatives find footing to deliver impact, it is timely to bring them under one roof. Together as CRIS, we seek to ensure a unity of mission across our programmes, synergise our capabilities, scientific resources and industry engagement. This way, we stay relevant and aligned to the needs of Singapore patients, healthcare system and researchers, and build long-term sustainability for these efforts,” said Dr Danny Soon, Chief Executive Officer of CRIS and Executive Director of SCRI.
At the CRIS official launch ceremony held on 6 April 2022, two of CRIS’s initiatives – ACTRIS and SCRI – announced the following partnerships:
Moving ahead, CRIS aims to build networks and collaborations for regional clinical trials, perform cost-effectiveness assessments for healthcare interventions, and foster industry engagement to fulfil the CRIS Vision – “to nurture and build cutting edge capabilities and innovation in clinical research and translation for Singapore”.
CRIS Chairman, Professor John Lim said: “With Singapore pivoting to a Healthier SG strategy, focusing on community and preventive care, CRIS will support MOH’s and national priorities by identifying impactful health-tech innovation through NHIC, supporting preventive health through appropriate implementation of precision medicine at PRECISE, gleaning a good understanding of cost-effectiveness in cancer and cell therapies at STCC and ACTRIS, and promoting an efficient environment for relevant clinical trials through SCRI. In this way, CRIS aims to keep Singapore at the forefront of clinical and translational research innovation, while actively advancing the sustainability, affordability and quality of Singapore’s healthcare system.”
For media queries, please contact:
Assistant Manager, Corporate Communications
Senior Manager, Corporate Communications
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
Delfi Diagnostics’ liquid biopsy test uses machine learning to spot changes in patients’ DNA fragmentation profiles that indicate the presence of cancerous cells.